Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia

Xerostomia Clinical Trial

Official title:

Multicenter Controlled Parallel-Groups Trial to Evaluate the Efficacy, Safety and Acceptability of TGO Buccal Spray Versus a Saliva Substitute in the Treatment of Psychotropic Medicines-Induced Xerostomia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00332618
• Other study ID #: Laboratoires CARILENE
• Status: Completed
• Phase: Phase 2
• First received: May 31, 2006
• Last updated: June 6, 2006
• Start date: September 2003
• Est. completion date: April 2004

Study information

• Verified date: March 2003
• Source: Laboratoires CARILENE
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of HealthUnited States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The objective of the trial was to evaluate the efficacy and clinical safety and acceptability of Oxygenated Glycerol Triesters in the relief of symptoms of xerostomia versus a reference comparator.

Description:

Xerostomia is due to inadequate (hyposialia) or inexistent (asialia) saliva secretion.

There are may causes. Transitory xerostomia may occur in the presence of anxiety (stage fright, fear or dehydration). Prolonged xerostomia is most often related to a systemic disease, certain medicines or to radiotherapy of the head or neck.

Salivation depends upon the autonomic (sympathetic and parasympathetic) nervous system for its production and on the central nervous system for stimuli-dependant excretion. Substances acting on alpha an beta sympathetic receptors, whether agonists or antagonists, may induce hyposialia. Atropine, the main antagonist of the parasympathetic system, is present in many medicines used for pulmonary, ophthalmic or neurological purposes, potentially causing hyposialia. Similarly, imipramine antidepressants, phenothiazine neuroleptics, antihistamines and disopyramide predispose to the onset of hyposialia.

Xerostomia is often accompanied by buccal signs such as impaired sense of taste, halitosis and buccal ulcers and interferes with functions such as speech, chewing and swallowing. Because of reduced salivary secretion , there is a disturbance of the microbial colonization of the buccal cavity. Xerostomia has significant untoward effects on the buccal cavity and the quality of life of patients.

The basis of the treatment of xerostomia involves the use of saliva substitutes and/or saliva stimulants. Oxygenated Glycerol Triesters is neither a replacement for nor stimulant of saliva. It is a lubricant and protective solution for endobuccal spray.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: April 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• men or women over 18 years of age

• with a diagnosis requiring the prescription of psychotropies (antidepressants, tranquilizers, etc) for more than 6 weeks

• having received no palliative treatment for xerostomia for a minimum of the past 2 weeks

• having xerostomia meeting the questionnaire selection criteria and the sialometer method parameters

• patients legally competent to give their consent

• capable of and accepting to participate in the trial and capable of and accepting to answer trial questionnaires

Exclusion Criteria:

• combined treatments incompatible with the trial, un particular alcoholic solutions

• diabetes, any buccal condition requiring antimicrobial treatment

• Sjögren's syndrome or othermedical causes of xerostomia

• current participation in other clinical trials

• patient suffering from cancer

• patients with allergy to or known intolerance of any of the constituents of the investigational products

• patients treated with pilocarpine

Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Xerostomia

Intervention

Device:
• OXYGENATED GLYCEROL TRIESTERS

Locations

Country	Name	City	State
France	Chu Hopital Des Broussailles	Cannes

Sponsors (1)

Lead Sponsor	Collaborator
Laboratoires CARILENE

Country where clinical trial is conducted

France, 

References & Publications (1)

Fox PC. Management of dry mouth. Dent Clin North Am. 1997 Oct;41(4):863-75. Review. — View Citation